Drug Profile
Nanoliposomal vinorelbine - Merrimack Pharmaceuticals
Alternative Names: NanoVNB; Vinorelbine encapsulated liposome - Taiwan Liposome CompanyLatest Information Update: 05 Nov 2021
Price :
$50
*
At a glance
- Originator HERMES BioSciences
- Developer Taiwan Liposome Company
- Class Antineoplastics; Small molecules; Vinca alkaloids
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 29 Nov 2010 Discontinued - Phase-II for Colorectal cancer in Taiwan (IV)
- 09 Oct 2007 Nanoliposomal vinorelbine is available for licensing in the US, Europe and Japan (http://www.hermesbio.com)
- 09 Oct 2007 Phase-II clinical trials in Colorectal cancer in Taiwan (IV)